455 charged in $6.5 billion health care fraud takedown; judge blocks rule limiting loans for nursing and PA students; Nature Medicine retracts cancer-timing study — Morning Medical Update Weekly Recap

455 charged in $6.5 billion health care fraud takedown

Ninety physicians and other licensed medical professionals were among those charged in the Justice Department's largest Medicaid enforcement action to date.

The Justice Department on Tuesday charged 455 defendants across 45 states and territories in connection with more than $6.5 billion in alleged false claims, including conduct prosecutors say caused serious patient harm. The action set records for Medicaid specifically, with 295 defendants and more than $518 million in alleged Medicaid losses.

Officials emphasized the government's growing reliance on data analytics to flag suspicious billing before payments go out, a shift compliance experts say increasingly puts individual physicians under scrutiny. Investigators seized more than $182 million in cash, vehicles and other assets, and CMS suspended or revoked the billing privileges of more than 2,400 individuals and entities. Read more.

Related content: Inside the 10 worst health care fraud cases of 2026 so far

Judge blocks rule that cut student loan access for nursing and PA students

The borrowing caps Congress set remain in place, but the advanced-practice pipeline many practices depend on won a reprieve.

A federal judge in Washington has blocked an Education Department rule that would have locked graduate students in nursing, physician assistant and other health fields into lower federal student loan limits. Under last year's tax and spending law, known as the One Big Beautiful Bill Act, students in professional programs such as medicine and law may borrow up to $50,000 a year, while other graduate students are capped at $20,500; the department's rule had limited that higher tier to 11 fields. The judge found the department exceeded what Congress wrote when it narrowed the definition of a "professional degree." She left the statutory borrowing caps intact and did not restore the uncapped loan program the law eliminated, making the ruling narrower than it first appears. Reuters has more.

Nature Medicine retracts study on timing of cancer immunotherapy

Editors said they no longer have confidence in results that tied morning infusions to far longer survival in lung cancer patients.

The journal Nature Medicine has retracted a Chinese clinical trial that found lung cancer patients who received immunotherapy in the morning lived nearly twice as long as those treated later in the day.

The February study prompted calls from patients asking to reschedule infusions, several oncologists said. In its retraction notice, the journal cited records changed midway through the trial, discrepancies between versions of the study plan and other irregularities, concluding it could no longer trust the integrity of the results. A separate analysis of more than 3,000 patients across eight studies found the timing of treatment is unlikely to meaningfully affect outcomes. The New York Times has the story.